Rexahn Pharmaceuticals (RNN +3.3%) moves up this morning after being initiated by analysts at Maxim with a Buy and a price target of $1.50 a share. The company specializes in oncology and CNS therapeutics, and has recently expanded its intellectual property around isoquinolinamine, a class of potent anti-cancer compounds, which provide potent anti-tumor activities in several human cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs